Kornimate/medical-research-clean huggingface dataset:
the mars® albumin dialysis system in patients with fulminant and subfulminant hepatic failure

Conditions: Hepatitis

Summary: the purpose of this study is to improve the survival rate of those patients with acute fulminant hepatitis through treatment with the mars® extra-corporal liver-purification system by: 1. reducing the number of patients who die before a graft is available 2. increasing the chances of survival without a liver transplant 3. reducing the pre- and post-operative mortality in transplant patients

patients with fulminant or subfulminant hepatitis with either an indication or a relative contraindication to a liver transplantation, are randomized to two groups: 1. a group treated with the conventional medical intensive treatment (including the hemodialysis techniques, continuous veno-venous hemofiltration or hemodiafiltration, if necessary) and the gold standard surgical treatment (liver transplantation) compared to 2. a group receiving, in addition to the conventional medical intensive treatment, albumin dialysis using the mars device and the gold standard surgical treatment (liver transplantation).

Eligibility criteria:
inclusion criteria: * patients with severe or sub-severe hepatitis, with an indication or a contraindication to liver transplantation exclusion criteria: * sepsis severe not controlled * haemorrhage activates not controlled * clinical obviousness of disseminated intravascular coagulation * severe pathology cardiopulmonary (nyha \> or = 2) * pregnancy, breast feeding * average blood pressure \< 40 mmhg more than 10 minutes in spite of a support by the inotrope * nonhepatic coma of origin * cholestases extra-hepatitic * antecedents of heavy surgery in the 4 previous weeks or surgical problems unsolved * absolute counter-indication with hepatic transplantation (extra neoplasia hepatic evolutionary, irreversible cerebral attack, irreversible multi-visceral failure, visceral tares contra-indicating the transplantation) * positive serology hiv * hepatic demonstrations of the malignant hemopathies * participation in another therapeutic test in the 4 previous weeks

Keywords: albumin dialysis mars system extracorporeal artificial liver support fulminant hepatitis subfulminant hepatitis acute liver failure
peripheral nerve block compared to intra-articular injection for taa post-operative pain

Conditions: Ankle Arthritis; Ankle Arthropathy

Summary: ankle arthritis is associated with debilitating pain and chronic disability. for the treatment of severe ankle arthritis, total ankle arthroplasty (taa) is one treatment option. postoperative pain management in joint arthroplasty is an ongoing and relevant issue. the purpose of this study is to examine if differences exist in postoperative pain control, overall patient satisfaction, and use of narcotics using an intra-articular injection in the operating room compared with a peripheral nerve block in patients undergoing taa.

this is a two-arm, prospective, randomized, controlled clinical study. use of intra-articular injections in taa are not widely reported in literature; however, they are commonly used during total knee arthroplasty's (tkas). the purpose of this study is to examine if differences exist in postoperative pain control, overall patient satisfaction, and use of narcotics using the intra-articular injection compared with a peripheral nerve block in patients undergoing taa. results will contribute to the literature for the best surgical practice for pain management following a taa for ankle arthritis. patients will be randomized to receive one of the following interventions for pain control in the operating room: 1. intra-articular injection 2. preoperative peripheral nerve block: the study aims are: * aim 1: determine if intra-articular injection as source of pain control for taa lowers postoperative pain as measured by self-reported narcotic use and pain vs. the peripheral nerve block. * aim 2: evaluate differences in functional outcomes and health related quality of life between intra-articular injections and peripheral nerve block as reported by pre- and post-operative patient questionnaires patients who consent to participate will complete study activities pre-operatively, and at 2 weeks, 6 weeks, and 3 months post-operatively.

Eligibility criteria:
inclusion criteria: * patient is 40 - 80 years old * patient is having a primary, unilateral taa * patient has signed the current, institutional review board approved informed consent document exclusion criteria: * patient has untreated endocrine disease * patient has uncontrolled diabetes; lab result of hemoglobin a1c level \> 8.0 mg/dl * patient has significant heart, liver, kidney or respiratory disease * patient has peripheral vascular disease * patient has active cancer * patient has current history of narcotic use beyond that of oral medications * patient discharge status is known to be to care facility
nutrition supplementation in cardiovascular surgery patients

Conditions: Malnutrition

Summary: this randomized controlled pilot study evaluates the use of oral nutritional supplementation in nutritionally at-risk cardiovascular surgery patients. the oral nutrition supplement is given for 30 days prior to surgery, continuing throughout their surgical hospitalization and ends at hospital discharge. half of the participants will receive the oral nutritional supplement and the other half will not.

cardiovascular surgery (cvs) is a resource intensive modality in the treatment of coronary artery disease and valvular heart disease. cvs patients who are malnourished experience increased duration of cardiopulmonary bypass, post-operative infections, impaired wound healing, muscle wasting, longer lengths of intensive care unit (icu) and hospital stay, higher readmission rates, higher treatment costs and marked increases in mortality. despite the devastating effects of malnutrition in these patients, physicians and health care practitioners are poor in respect to identification, monitoring and treatment of malnutrition. in two large tertiary hospitals in ontario, this will be a randomized trial of a novel nutritional pathway to rapidly identify at-risk cvs patients pre-operatively, and then provide oral nutritional supplementation (ons) during the 30 days prior to surgery, then continue supplementation throughout hospitalization until discharge. meaningful patient-centered and economic outcomes will be examined.

Eligibility criteria:
inclusion criteria: 1. require cardiovascular surgery 2. have been assessed in a pre-operative clinic 3. have an intermediate or high risk society of thoracic surgeons (sts) score 4. malnutrition universal screening tool (must) score of \>1. exclusion criteria: 1. require urgent/emergent cardiovascular surgery 2. have advanced symptomatic angina or heart failure 3. are designated palliative care 4. are currently suffering from refeeding syndrome 5. have a pre-existing medical condition that prevents oral intake of full fluids 6. are on a fluid restricted diet 7. are unable to walk prior to current illness 8. have a current diagnosis of diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome 9. are pregnant or currently breastfeeding.
vancomycin dosage strategy based on a trough concentration model

Conditions: Pneumonia, Staphylococcal

Summary: study design: allocation: randomized endpoint classification: efficacy study masking: open label primary purpose: treatment primary endpoint: incidence of reaching the target serum trough concentration secondary endpoint: clinical efficiency, antibiotic use, acute kidney injury.

this is a prospective randomized control trial. there are two groups, study group and control group. patients of study group accepted vancomycin strategies decided by a serum trough concentration model, and patients of control group accepted vancomycin dosage decided by attending physician. the primary endpoint is the incidence of reaching the target serum trough concentration, the secondary endpoint are clinical efficiency, antibiotic use and side effects such as acute kidney injury, etc.

Eligibility criteria:
inclusion criteria: * patients with doubted or diagnosed methicillin-resistant staphylococcus aureus severe pneumonia, and need vancomycin treatment. * sixty years and older. exclusion criteria: * younger than 60 years old * accepted blood purification therapy * pregnancy * positive hiv antibody titre * had known or suspected tuberculosis or other infections caused by fungi at baseline.

Keywords: pneumonia vancomycin trough concentration elderly patients
accuracy performance verification of the invos™ system in pediatrics

Conditions: Cerebral Oxygenation; Pediatric ALL

Summary: prospective, observational, multi-center trial designed to capture calibration and performance evaluation data with the invos™ system.

the purpose of this study is to verify invos™ cerebral oximetry system performance in pediatric and infant patients bycomparing regional oxygen saturation (rso2) values to reference blood oxygen saturation measurements obtained throughinternal jugular vein and arterial blood convenience sampling according to international organization on standards (iso) 80601-2-85:2021.

Eligibility criteria:
inclusion criteria: 1. under 21 years of age 2. meets weight requirement for sensors under study 3. scheduled for a diagnostic or interventional cardiac catheterization procedure with general anesthesia or sedation 4. arterial and venous access as part of the planned catheterization procedure exclusion criteria: 1. prior known severe allergies to medical grade adhesive/tape (band-aid) \[self-reported\] 2. a skin condition at the sensor site (e.g., rash, abrasion, laceration) 3. craniofacial disease producing abnormal forehead anatomy and/or preventing forehead application of the sensor 4. a known structural brain lesion beneath the sensor 5. known hemoglobinopathy 6. inability to lie supine with neutral neck position during catheterization 7. cerebrovascular disease 8. an emergent, life threatening condition impacting study conduct 9. unwillingness or inability to sign informed consent (ic) or assent by the parents/guardians of child 10. currently receiving phototherapy for bilirubin 11. arterial or venous anatomy that would preclude obtaining an accurate paired sample 12. known pregnancy

Keywords: cerebral oximetry pediatric infant
a pilot comparison of short-course nitrofurantoin in females with uncomplicated bacterial cystitis in the emergency department

Conditions: Uncomplicated Bacterial Cystitis

Summary: pilot study to compare the efficacy and safety of 3-day, twice-daily regimens of nitrofurantoin and ciprofloxacin in emergency department (ed) patients presenting with ubc.


Eligibility criteria:
inclusion criteria: * pre-menopausal females * ages 18-45 years old * symptoms of a uti (dysuria, frequency, urgency) exclusion criteria: * onset of symptoms \>7 days prior to the ed visit * non-english speaking * symptoms of pyelonephritis * diabetic * indications of sepsis * immunocompromised * currently using prophylactic antimicrobials * medications that could interfere with study drug * pregnant * lactating * history of kidney or liver disease * vaginal symptoms * presence of a urinary catheter * treatment for ubc \<2 weeks prior to ed visit * known allergy to study drug * unavailable for follow-up
observational study of pharmacological treatment for premature ejaculation concurrent with erectile dysfunction

Conditions: Premature Ejaculation; Erectile Dysfunction

Summary: premature ejaculation (pe) is a common disease in the andrology clinic. currently, the effectiveness and outcome differences of drug treatment still need to be studied and demonstrated. premature ejaculation concurrent with erectile dysfunction (ed) is common in outpatient clinics. the preferred treatment plan for these patients still needs to be further studied and explored, and the difference in the efficacy of different treatment regiments remain to be evaluated.


Eligibility criteria:
inclusion criteria: 1. pe concurrent with ed: the ielt is less than 3 minutes, the pedt score is ≥11 points, and 5≤iief-5≤21 points. 2. 18-60 years old, outpatient or physical examination population, with regular sex partners and regular sex life; 3. having the data below,and willing to participate in the trial（1）demographic information: age, gender, nationality, birthplace, etc;(2) physical examination data: height, weight, abdominal circumference, blood pressure, heart rate, etc ;(3) medical history data: history of present illness, past medical history, family history, etc;(4) scale evaluation: premature ejaculation diagnostic tool (pedt), premature ejaculation profile (pep), international erectile function score-5(iief-5), erectile hardness grading score (ehgs), clinical global impression of change (gicc); exclusion criteria: 1. age \ 60 years; 2. there is a history of acute and chronic diseases, major trauma and surgery, etc; 3. a long history of medication; 4. there is a history of unstable myocardial infarction and cerebral infarction; 5. a history of cardiogenic shock, severe heart failure, severe ventricular arrhythmia, etc; 6. there are serious diseases such as malignant tumors, chronic liver and kidney diseases, etc.
optical head-mounted display technology for low vision rehabilitation

Conditions: Retinal Dystrophies; Healthy

Summary: the goal of this study is to examine the ability of optical head-mounted display technology to enlarge the visual field of patients with severe visual field loss due to retinal dystrophy and to improve mobility and patient-reported outcomes.

worldwide it is estimated that 191 million people have moderate to severe visual impairment (msvi) and an additional 32.4 million are blind. patients with uncorrectable msvi may undergo low vision rehabilitation (lvr), which has been shown to improve functional abilities, such as mobility. however, existing lvr strategies do not adequately address severe visual field constriction. in this pilot study, the investigators will test the hypothesis that optical head-mounted display (hmd) technology expands constricted visual fields and improves mobility outcomes for patients with retinal dystrophy. we will use the moverio hmd platform which is considered a non-significant risk device. outcomes for patients with retinal dystrophy will be compared to normal age-matched controls.

Eligibility criteria:
inclusion criteria for subjects with retinal dystrophy: * diagnosis of retinal dystrophy * severe vision loss that constitutes legal blindness * able to perform a reliable goldmann visual field test * constricted visual field less than or equal to 20 degrees by goldmann perimetry using the iii4e stimulus in at least one eye with best-corrected visual acuity ≥ 20/60 inclusion criteria for control subjects: * healthy controls * visit history with the comprehensive and pediatric ophthalmology services at the university of michigan * able to perform a reliable goldmann visual field test exclusion criteria for subjects with retinal dystrophy: * movement disorder that precludes evaluation of mobility * functional vision loss * pregnant women exclusion criteria for control subjects: * visually significant ocular condition other than correctable refractive error * movement disorder that precludes evaluation of mobility * functional vision loss * pregnant women
mapping diabetes in quebec: validating medico-administrative algorithms for type 1 diabetes, type 2 diabetes and lada

Conditions: Diabetes Mellitus, Type 1; Diabete Type 2; Diabetes;Adult Onset; Diabetes, Autoimmune

Summary: the goal of this observational study is to validate medico-administrative algorithms that classify diabetes phenotypes (type 1, type 2, and latent autoimmune diabetes in adults - lada) in a population-based cohort in quebec, including children, adolescents, and young adults up to 40 years old with diagnosed diabetes. the main questions it aims to answer are: can these algorithms accurately distinguish between type 1, type 2, and lada across different age groups? what is the prevalence and incidence of each diabetes phenotype in quebec? participants will have their medical and administrative data analyzed, including data on medication usage and healthcare visits, to validate the accuracy of the algorithms. the study will involve comparing these algorithm-based classifications with clinical diagnoses or self-reported data to ensure reliability.

the goal of this observational study is to validate the effectiveness of medico-administrative algorithms developed to classify diabetes phenotypes, specifically type 1, type 2, and latent autoimmune diabetes in adults (lada), in a population-based cohort in quebec. the study focuses on children, adolescents, and young adults up to 40 years old who have been diagnosed with diabetes. the main questions it aims to answer are: can these algorithms accurately differentiate between type 1, type 2, and lada across various age groups? what are the prevalence and incidence rates of these diabetes phenotypes in the quebec population? participants, who are already diagnosed with one of the three diabetes types and receiving standard medical care, will have their data collected from existing medical and administrative records. this data includes information on medication usage, healthcare visits, and self-reported health outcomes. the study will involve a retrospective analysis where the classifications made by the algorithms will be compared with clinical diagnoses and self-reported data to determine the accuracy and reliability of the algorithms. this validation process is crucial for improving diabetes management and public health strategies by ensuring that these algorithms can be reliably used in broader epidemiological studies.

Eligibility criteria:
inclusion criteria: * individuals diagnosed with type 1, type 2, or latent autoimmune diabetes in adults (lada) based on clinical or self-reported data. * participants diagnosed between 1997 and 2024. * residents of quebec with available medico-administrative records from 1997 to 2024. exclusion criteria: * non-residents of quebec during the study period.

Keywords: medico-administrative algorithms cohort study observational study diabetes
lifevest post-cabg registry

Conditions: Sudden Cardiac Death; Ventricular Fibrillation; Ventricular Tachycardia; Ventricular Dysfunction; Myocardial Ischemia

Summary: this is a multi-center prospective registry of patients with an ejection fraction (ef) ≤ 35% following coronary artery bypass graft (cabg) surgery in order to test the hypothesis that wearable defibrillators (wd) will decrease overall mortality after discharge by decreasing arrhythmic death in this select population with high risk for sudden cardiac death (scd). this is a pilot project to determine the feasibility of a larger-scale study.


Eligibility criteria:
inclusion criteria: * patients who have undergone cabg surgery during current hospitalization * patients who have an ejection fraction ≤ 35% following the surgery. * patients who have dilated cardiomyopathy or prior myocardial infarction. * patients who are prescribed a wearable defibrillator following surgery. * patient who are at least 18 years old. exclusion criteria: * patients who have an active icd. * patients who have an active unipolar pacemaker. * patients having a chest circumference over 56 inches or under 26 inches. * patients who are unable to consent or unwilling to wear the wcd after discharge or who do not agree to be contacted at 90 days. * patients with a mental, visual, physical or auditory deficit that could impair their ability to properly interact with a wearable defibrillator. * patients participating in another clinical study with mortality as the primary endpoint. * patients unable to use a wearable defibrillator due to physical conditions (bandages preventing electrode contact, physical deformities preventing electrode contact, dextrocardia, etc.). * patients who have decided to forgo resuscitation.

Keywords: coronary artery bypass grafting resuscitation sudden cardiac death ventricular dysfunction
chemotherapy followed by peripheral stem cell transplantation in treating metastatic triple-negative breast cancer

Conditions: Carcinoma Breast Stage IV

Summary: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

to explore the progression-free survival of patients with metastatic triple-negative breast cancer treated with peripheral blood stem cell transplant (pbsct) followed by high dose chemotherapy.

Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) 0 or 1. * histologically or cytologically proven diagnosis of breast cancer with evidence of locally recurrent or metastatic disease. * documentation of estrogen and progestin receptor (er/pr) negative status and her2/neu receptor negative status (ie, fish negative or immunohistochemistry 0 or +1). * obtained complete response or good partial response after first line chemotherapy. * normal organ function required prior to study entry. * willingness to comply with treatment plans and other study procedures. exclusion criteria: * uncontrolled central nervous system (cns) involvement with disease * fertile women unwilling to use contraceptive techniques during treatment * females who are pregnant * organ dysfunction. * patients may not be receiving any other investigational agents.

Keywords: triple negative breast cancer autologous hematopoietic stem-cell transplantation